Anti-nerve growth factor in pain management: current evidence
about
Preventing painful age-related bone fractures: Anti-sclerostin therapy builds cortical bone and increases the proliferation of osteogenic cells in the periosteum of the geriatric mouse femur.Mechanism and therapeutic effectiveness of nerve growth factor in osteoarthritis painCombining Human and Rodent Genetics to Identify New Analgesics.Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?Nerve growth factor: a neuroimmune crosstalk mediator for all seasons.A Review on Ubiquitination of Neurotrophin Receptors: Facts and Perspectives.Recent advances in understanding and managing cancer painDepletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignanciesMolecular Mechanisms That Contribute to Bone Marrow PainFunctional and Molecular Characterization of Mechanoinsensitive "Silent" Nociceptors.Immunohistochemical localization of nerve growth factor, tropomyosin receptor kinase A, and p75 in the bone and articular cartilage of the mouse femur.Physiologic facet capsule stretch can induce pain & upregulate matrix metalloproteinase-3 in the dorsal root ganglia when preceded by a physiological mechanical or nonpainful chemical exposure.The neurotrophic tyrosine kinase receptor TrkA and its ligand NGF are increased in squamous cell carcinomas of the lung.Nerve Growth Factor and Pathogenesis of Leprosy: Review and Update.Anti-nerve growth factor therapy attenuates cutaneous hypersensitivity and musculoskeletal discomfort in mice with osteoporosis.
P2860
Q37426026-16A2148C-6FCA-46C6-86BC-A7BEA5E001A4Q38641435-48344C90-87B3-49A2-AD6A-AB7B17717E69Q38699127-DC09E08D-2D85-4A00-B385-B70476E8C864Q38817280-9057F9C6-5A12-45AE-B431-250549621E3BQ39098815-C88ABC17-BD40-44AB-A423-B0C4BCEB2CCCQ39196632-A4A8EF51-7358-45E4-A753-A4E67E7C765EQ39424734-1731429B-B213-474F-AFC8-57A66859D1E9Q41475920-9AE71F99-431B-450D-8B8F-D69DE82D7F4BQ41684342-006A56D7-21A6-476B-9376-01B7B151666AQ47099480-0CDA6EF2-9C09-42AA-BE7B-BA0F57FE6AE2Q47111283-FC9184BB-48F8-4D8D-A0E9-A1A8AA4838F2Q52663819-E57143CD-99E0-4023-99A0-2042DD113EC2Q54978149-7E56B587-A2B3-4C68-B8BC-F7F98353BE3BQ55005540-070B1385-D5CD-49B5-A774-2F05214F475DQ55318070-76714B54-6314-42F1-8D10-6F57EB8C85A4
P2860
Anti-nerve growth factor in pain management: current evidence
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Anti-nerve growth factor in pain management: current evidence
@ast
Anti-nerve growth factor in pain management: current evidence
@en
Anti-nerve growth factor in pain management: current evidence
@nl
type
label
Anti-nerve growth factor in pain management: current evidence
@ast
Anti-nerve growth factor in pain management: current evidence
@en
Anti-nerve growth factor in pain management: current evidence
@nl
prefLabel
Anti-nerve growth factor in pain management: current evidence
@ast
Anti-nerve growth factor in pain management: current evidence
@en
Anti-nerve growth factor in pain management: current evidence
@nl
P2093
P2860
P3181
P356
P1476
Anti-nerve growth factor in pain management: current evidence
@en
P2093
Daniel G Hottinger
David S Chang
Eugene Hsu
Steven P Cohen
P2860
P304
P3181
P356
10.2147/JPR.S89061
P407
P577
2016-01-01T00:00:00Z